Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme

Ren-Yuan Bai, Verena Staedtke, Colette M. Aprhys, Gary L. Gallia, and Gregory J. Riggins

Ludwig Collaborative Laboratory, Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland

Glioblastoma multiforme (GBM) is the most common and aggressive brain cancer, and despite treatment advances, patient prognosis remains poor. During routine animal studies, we serendipitously observed that fenbendazole, a benzimidazole antihelminthic used to treat pinworm infection, inhibited brain tumor engraftment. Subsequent in vitro and in vivo experiments with benzimidazoles identified mebendazole as the more promising drug for GBM therapy. In GBM cell lines, mebendazole displayed cytotoxicity, with half-maximal inhibitory concentrations ranging from 0.1 to 0.3 μM. Mebendazole disrupted microtubule formation in GBM cells, and in vitro activity was correlated with reduced tubulin polymerization. Subsequently, we showed that mebendazole significantly extended mean survival up to 63% in syngeneic and xenograft orthotopic mouse glioma models. Mebendazole has been approved by the US Food and Drug Administration for parasitic infections, has a long track-record of safe human use, and was effective in our animal models with doses documented as safe in humans. Our findings indicate that mebendazole is a possible novel anti-brain tumor therapeutic that could be further tested in clinical trials.

Keywords: albendazole, animal models, antiparasitic, benzimidazole, drug discovery, glioblastoma, mebendazole, preclinical trial, tubulin.

Glioblastoma multiforme (GBM), which has been classified as a grade IV astrocytoma, is a highly aggressive tumor that invades early into surrounding brain tissues, making cure via surgical resection almost impossible. Standard of care currently consists of radiotherapy combined with chemotherapy of DNA-alkylating/methylating temozolomide (TMZ), which has increased the mean duration of patient survival to 15 months. Currently, only 10% of patients with GBM, including all post-treatment living conditions, survive 5 years after diagnosis, despite continuous work and improvement of GBM therapy.

There has been no shortage of clinical trials for GBM. More than 600 clinical trials related to GBM have been run or are actively recruiting, according to the US National Institutes of Health’s website (http://www.ClinicalTrials.gov). Unfortunately, few if any recent clinical trials show a clear survival benefit for patients with GBM. The present clinical trial system often does not address the difficulties of GBM therapy. Many therapies tried in the clinic were developed on the basis of results for other cancers, do not account for insufficient drug delivery to the brain, and do not address treatment-resistant migrating glioblastoma cells.

There is a need to broaden the available treatments for GBM by introducing new therapeutic agents. One possible means to expedite initiation of GBM clinical trials is to examine previously established drugs with known track records of safety in humans, regardless of their intended use. However, searching for anticancer activity in compounds that have been “generally regarded as safe” may or may not turn up a promising drug suitable for GBM.

Mebendazole (MBZ), methyl N-[6-{benzoyl}-1H-benzimidazol-2-yl] carbamate, is a drug developed to treat human helminthic infections. It has been approved by the US Food and Drug Administration (FDA) and is available as generic drug for treating roundworm, common hookworm, American hookworm, pinworm, and whipworm. Clinical application of MBZ has been well documented at various doses for the rarer echinococcosis (hydatid disease). The closely related albendazole (ABZ) has been approved for treating an even...
wider range of parasites, including neurocysticercosis in the central nervous system (CNS). Both drugs are used to treat CNS parasitic infections and, therefore, have sufficient brain penetration for these indications. Sufficient drug delivery to the tumor remains a major challenge for most glioblastoma therapy.

The mechanism of action for MBZ and other benzimidazoles is to bind to the tubulin subunits in the gut epithelium of the parasite, preventing polymerization of the tubulin, causing ultrastructural changes, and eventually preventing parasite growth.9,10 Tubulin is vital to cell division and is also a cancer target for several chemotherapy drugs, including paclitaxel, cholicicine, and vincristine.

In addition to antiparasitic activity, MBZ and ABZ have shown preclinical anticancer activity in adenocortical carcinoma, lung cancer, ovarian cancer, and melanoma cells,11–15 but thus far, the benzimidazole family has not been tested against glioblastoma or any other brain tumors.

Fenbendazole, a benzimidazole antihelminthic used routinely in veterinary medicine, was applied as feed supplement in our mouse colony to fight a pinworm infection. We noted problems with brain tumor intake in the xenograft model after the mice were given fenbendazole, and we further investigated this finding. This eventually led us to test the efficacy of the approved human drugs MBZ and ABZ against GBM in vitro and in vivo. We also tested whether MBZ’s predicted interaction with tubulin was evident in glioblastoma cells. We found that MBZ worked best to extend survival in 2 different animal models and to explain our findings.

Materials and Methods

Cell Lines and Tissue Culture

Human GBM U87-MG (U87), D54, H80, H247, H392, H397, H502, H566, and the mouse GL261 glioma cell line were maintained in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics. The human GBM neurosphere line 060919 was grown in NeuroCult Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and antibiotics. The human GBM 060919 stem-like neurosphere cells were transfected with firefly luciferase and lentivirus, CMVΔR8.91 and pMD.G in 293T cells using Lipofectamine 2000 (Invitrogen). Virus was harvested after 48 h and used to infect GL261 and 060919 cells by incubating with 8 μg/mL polyberekine (Sigma).

Animal Experiments

Female C57BL/6 mice (age, 5–6 weeks) were purchased from the NCI. The syngeneic cell line GL261 was transfected with firefly luciferase with lentivirus and used for brain tumor implantation. For the implantation procedure, female C57BL/6 mice were anesthetized via intraperitoneal injection of 60 μL of a stock solution containing ketamine hydrochloride (75 mg/kg; 100 mg/mL; ketamine HCl; Abbot Laboratories), xylazine (7.5 mg/kg; 100 mg/mL; Xyla-ject; Phoenix Pharmaceutical), and ethanol (14.25%) in a sterile 0.9% NaCl solution. Using a stereotactic frame, 40,000 GL261 cells were injected through a burr hole drilled 2 mm lateral to the sagittal suture and 1 mm anterior to the coronal suture at a depth of 3 mm below the dura at a rate of 1 μL/min.

The human GBM 060919 stem-like neurosphere cells were transfected with firefly luciferase and lentivirus, and 150,000 cells were implanted in female athymic nude mice, as described above.

At day 5 after implantation of the tumor cells, drugs were administered by oral gavage. MBZ tablets (TEVA) and ABZ tablets (GlaxoSmithKline) were resuspended in phosphate-buffered saline (PBS) and mixed with 50% of sesam oil (Sigma) to achieve better gastrointestinal absorption of the drug.5,16 Control animals were fed with PBS mixed with 50% sesam oil. TMZ was dissolved fresh for each use in PBS.

Animals were observed daily for any signs of deterioration, neurotoxicity, or movement disorders. They were inspected for signs of pain and distress, as in accordance with the Johns Hopkins Animal Care and Use Guidelines. If the symptoms persisted and resulted in debilitation, the moribund animals were euthanized according to protocol. The brain and other organs were dissected and placed in formalin for additional pathological studies.

Intracranial luciferase activity was determined by a Xenogen instrument with intraperitoneal injection of 2 mg/mouse D-luciferin potassium salt (Gold

by the Developmental Therapeutics Program of the National Cancer Institute (NCI)/National Institutes of Health. The viable cells were measured with a Cell Counting Kit-8 (Dojindo Laboratories) containing WST-8 tetrazolium salt at 450 nm on a PerkinElmer VICTOR 3 plate reader. Half-maximal inhibitory concentrations (IC50s) were determined by incubating cells at a range of concentrations for 72 h and calculated by GraphPad Prism, version 5.0, using the log(inhibitor) versus response function and nonlinear fit.

Luciferase Expression by Lentivirus

The firefly luciferase cDNA from pGL3-basic (Promega) was subcloned in pFUGW and transfected along with CMVΔR8.91 and pMD.G in 293T cells using Lipofectamine 2000 (Invitrogen). Virus was harvested after 48 h and used to infect GL261 and 060919 cells by incubating with 8 μg/mL polyberekine (Sigma).
Biotechnology). Fifteen minutes after the injection, the animals were scanned for 1 min at a distance of 20 cm.

**Tubulin Polymerization Assay**

The tubulin polymerization assay was performed as described elsewhere.

In brief, cells were lysed by resuspension in hypertonic buffer (2 mM of ethylene glycol tetraacetic acid, 1 mM of MgCl2, 2 mM of phenylmethylsulfonyl fluoride, 0.5% NP40, 20 mM of Tris-HCl [pH 6.8], and protease inhibitors). After brief vortexing, the samples were centrifuged at 13,000 g for 10 min at room temperature. The supernatant containing the depolymerized tubulin was transferred to a new tube, and the pellet containing the polymerized tubulin was resuspended in an equal volume of hypertonic buffer. Equal amounts of protein were analyzed by Western blotting. The anti-α-tubulin Western blots were scanned, and the signals were qualified by the program ImageJ 1.42q (National Institutes of Health).

**Western Blots**

Cells were lysed in buffer as previously described elsewhere. Cell lysates were heated for 5 min with LDS Sample Buffer (Invitrogen) supplemented with 100 mM of dithiothreitol before loading onto a 4%–12% NuPAGE Bis-Tris Gel (Invitrogen). After transfer to a polyvinylidene fluoride membrane (Bio-Rad), immunostaining was performed in accordance with standard procedure. The following antibodies were used in this study: mouse anti-α-tubulin (Calbiochem) and anti-actin-HRP (Santa Cruz, C-11). Signals were visualized by the SuperSignal chemiluminescent system (Pierce).

**Immunofluorescence Staining**

The staining procedure followed the procedure described above. The neurosphere glioblastoma cell line 060919 was transferred from neurosphere medium and grown in DMEM medium containing 10% PBS in adherent single cell condition on chamber slides (Nunc). They were treated with 1 μM of MBZ or 10 nM of cholicchine for 24 h and then fixed for 10 min with 4% paraformaldehyde solution and permeated with methanol for 2 min with 3 washes in PBS in between and after. The slides were first blocked by 10% goat serum in PBS at room temperature. They were then washed 3 times in PBS in between and after. After staining, the slides were covered with mounting medium containing DAPI (Vector Laboratories) and examined on a fluorescence microscope.

**Statistical Analysis**

The results are presented as a mean value ± standard deviation. Data were analyzed by GraphPad Prism, version 5.0. The P values were determined by a Mantel-Cox test. P values <.05 were accepted as statistically significant.

**Results**

We first observed the anti–brain tumor activity of benzimidazole family anthelmintics serendipitously when the animal facility started providing fenbendazole-containing food to the mice colony to eliminate pinworm infections. One of our orthotopic brain tumor models stopped forming tumors, whereas before the fenbendazole therapy, we had consistent, reproducible tumor engraftment. This prompted us to investigate commercially available benzimidazoles: fenbendazole, thiabendazole, MBZ, and ABZ, by first using GBM cell lines in vitro. On the basis of superior IC50 levels (Fig. 1A and data not shown) and FDA approval of human use, we decided to focus on MBZ and ABZ for in vivo preclinical evaluation.

We used a GL261 syngeneic mouse glioma model to test the in vivo efficacy of MBZ and ABZ. The syngeneic GL261 mouse glioma was induced originally by intracranial injection of 3-methylcholanthrene into C57BL/6 mice. Intracranial GL261 tumors showed rapid growth, diverse cell populations, necrotic regions, and invasive growth pattern, along with hemorrhages, closely resembling human GBM pathology (Fig. 1B). GL261 cells in vitro were susceptible to MBZ and ABZ, with IC50 levels measured at 0.24 and 0.3 μM, respectively (Fig. 1A). In a dose escalation in C57BL6 mice, daily administration of MBZ at 100 mg/kg led to toxicities, such as weight loss, whereas administration at 30 mg/kg did not show adverse effects.

Oral administration of MBZ at 50 mg/kg from day 5 after tumor implantation slowed tumor growth. The GL261 tumors expressing luciferase were visualized via Xenogen scanning using luciferin, showing smaller tumors after 20 days of MBZ treatment, as reflected by the significantly lower luciferase signals versus those of the control group (Fig. 1C). Mean survival was increased from 30 days in the control group to 49 days in the intervention group, a 63.3% increase (Fig. 1D).

ABZ was tested with the GL261 model at 50 mg/kg and 150 mg/kg, also without showing any significant adverse effects. Compared with the same control group in Fig. 1D, 2 doses of ABZ were able to moderately extend the survival to 36 days (20%) and 39 days (30%), respectively (Fig. 1E). This survival increase was less than that with MBZ.

Next, we tested MBZ and ABZ with the 060919 human GBM stem-like neurosphere cell line. The IC50s of both drugs in vitro were determined to be similar (~0.1 μM). Of note, this cell line showed resistance to TMZ compared to the GL261 line, with an IC50 at 148 μM (Fig. 2A). The 060919 line grown as an intracranial xenograft showed a highly invasive and neo-vascularized growth pattern similar to the morphology of human GBMs, with features such as brain tissue infiltrations, heterogeneous population, hemorrhages,
neoplastic giant cells, necrotic/hypoxic tissues, and pseudopalisading cells21 (Fig. 2B). Treating the mice with MBZ prolonged the mean duration of survival to 65 days, compared with 48 days for the control group, whereas ABZ at 150 mg/kg and TMZ at 15 mg/kg failed to extend the duration of survival (Fig. 2C). The measurement of luciferase activity in 060919 tumors confirmed that the tumor growth was inhibited by MBZ treatment (Fig. 2D and E).

Benzimidazole family antihelminthics can exert cellular toxicity by binding to tubulin molecules and thereby disrupting their polymerization and microtubule formation in a similar fashion to colchicines.22 To test whether MBZ interferes with the microtubule formation in GBM cells, we performed a tubulin polymerization assay with the 060919 GBM cell line. Cells were incubated with 0.1 or 1 μM of MBZ, 1 μM of colchicines, or 10 nM of paclitaxel (PTX) for 24 h. PTX is known for hyperstabilizing the microtubule structure, thus causing mitotic arrest. After the lysis by hypotonic buffer and centrifugation, polymerized and depolymerized tubulin resided in the pellet and supernatant fractions, respectively. One μM of MBZ clearly reduced the polymerized tubulin in the pellet as well as the percentage of polymerized tubulin in the total tubulin amount down to 11%, compared with 38% for the control group (Fig. 3A and B). Accordingly, colchicine severely decreased polymerized tubulin down to 1%, and PTX accumulated it up to 80%. Supplementary Material, Figure S1 shows the antitubulin polymerization of MBZ at 0.1 or 0.2 μM after 72 h, and the concentrations and time were comparable to the results of the condition used to determine the IC50 value of MBZ with 060919 cells. After 72 h, MBZ significantly inhibited the polymerization of tubulin at 0.1 μM. The depolymerization of tubulin by MBZ caused serious disruption in microtubule structure, as demonstrated by the immunofluorescent staining of α-tubulin in Fig. 3C, in which 060919 GBM stem cells were cultured adherently on the chamber slides and incubated with 1 μM of MBZ for 24 h. As a positive control, colchicine showed a similar effect.

To evaluate MBZ therapy in combination with TMZ, we first tested the in vitro efficacies of MBZ and TMZ...
using 10 GBM cell lines. Although the IC$_{50}$s of MBZ appeared to be in a close range, between 0.11 and 0.31 μM, these cell lines varied widely in response to TMZ with IC$_{50}$s ranging from 8.7 to 547 μM (Fig. 4A). When used together in vitro, the combination of MBZ and TMZ slowed growth in GBM cells more than either drug alone (Fig. 4B). However, synergy was not observed in vivo. In the GL261 mouse model, TMZ at 15 mg/kg prolonged the mean survival to 41 days, compared with 29 days in the control group, in this set of experiments. With the addition of MBZ to the treatment regimen, the mean survival was extended to 50 days (Fig. 4C). This was a 72.4% improvement over the untreated control group. However, it is not significantly longer than the survival benefit achieved by MBZ alone observed in the previous set of experiments in Fig. 1D. Because the experiments were done under the same conditions, the various studies are shown superimposed in Supplementary Material, Fig. S2 for direct visual comparison.

### Discussion

We accidentally found that fenbendazole, a benzimidazole, reduced brain tumor engraftment in nude mice after the mouse colony was treated for pinworms. Fenbendazole was previously reported to interfere with one lymphoma model in 2008, after we had already noted problems with fenbendazole disrupting brain tumor engraftment. We pursued this finding by evaluating whether the 2 most widely used human approved benzimidazoles showed efficacy against glioblastoma models.

The benzimidazoles are widely used for veterinary and human applications, with MBZ and ABZ approved for human parasitic treatment. Benzimidazole drugs, such as MBZ and ABZ, have been used to treat CNS infections of human cystic and alveolar echinococcosis since the introduction in the 1970s and have proven to be well tolerated and safe. Although MBZ and other benzimidazoles have reported preclinical antitumor
activity, this is, to our knowledge, the first study to have related benzimidazole drugs to the treatment of a brain cancer. MBZ showed efficacy in 2 mouse models, with both having histological and phenotypic features similar to human GBM.

Although ABZ and MBZ revealed similar IC₅₀s with both GL261 mouse glioma cells and 060919 human GBM stem-like neurosphere cells, MBZ extended survival most effectively. One explanation may be the different bioavailability of MBZ versus ABZ in our models. The limited solubility of ABZ and MBZ in water and organic solvents greatly affects absorption and behavior in the body. Given orally, ABZ and MBZ suffer from poor gastrointestinal absorption in human and rodents, and fatty meals are usually included to increase the absorption. The absorption of MBZ has been reported to be as low as 5%–10%, and similar low levels have been measured with ABZ in humans. We decided to focus on MBZ because of its superior efficacy.

MBZ and ABZ bind to the (+) end of the microtubule, inhibit tubulin polymerization, and prevent the addition of tubulin subunits in parasites. Microtubules are composed of α- and β-tubulin and are cytoskeleton components that are required for cellular transport, cell division, and maintenance of structural integrity. In addition, disruption of microtubule formation could also impair the migration of GBM cells. It was shown that the migration of neuronal cells is impaired by an α-tubulin mutation and that microtubule inhibitors can potentially block the mobility of glioma cells. It is also very likely that the migration/invasion feature of GBM cells renders them more resistant to apoptosis and cytotoxic insults. Figure 3 shows significant reduction of polymerized tubulin in 060919 cells treated with 1 µM of MBZ, as well as the disruption of microtubule structure. Other mechanisms have been proposed for benzimidazole, such as inhibition of VEGF and HIF-1α expression and inactivation of Bcl-2. Despite clear evidence of an anti-tubulin effect from MBZ, other mechanisms contributing to its efficacy in our preclinical models cannot be excluded. In parasites, a specific resistance to benzimidazoles was found to be conferred by changing the β-tubulin sequence at codon 200 as the result of a single-nucleotide polymorphism from TTC200 to TAC200. The possibility of tubulin mutation-based acquired resistance should be noted if MBZ therapy proceeds to clinical trials.

Antitubulin drugs other than benzimidazoles have been studied for cancer treatments, but many, such as
cholchicine, exhibit severe toxicity. MBZ, flubendazole, and a number of benzimidazoles have been shown to interact with tubulin on the similar binding site—like colchicines, but distinct from the binding site of vinca alkaloids.\(^{22,34,35}\) Vinca alkaloids, such as vinblastine and vincristine, have been approved for treating lymphomas, acute lymphoblastic leukemia, and nephroblastoma but are associated with considerable adverse effects, including bone marrow suppression and nervous system toxicity.

MBZ and other benzimidazoles seem to target cancer cells preferentially over normal cells, and this may suggest a favorable therapeutic index for in vivo applications. In vitro, MBZ displayed a slightly higher IC\(_{50}\) of 0.4 \(\mu\)M in mouse astrocytes, compared with those in various GBM cell lines, ranging 0.11–0.31 \(\mu\)M. In addition, our 2 different GBM animal models showed survival benefit for MBZ with minimal toxicity. Several other studies have shown in vivo success with benzimidazoles against cancers, including non–small cell lung cancer, adenocortical carcinoma, leukemia, and colorectal cancer.\(^{11,12,23,35,36}\) There is evidence that MBZ’s mode of action in lung cancer cells involves prevention of polymerization of tubulin.\(^{12}\) An additional anti-cancer mechanism associated with MBZ is that it induces apoptosis by BCL-2 inactivation in melanoma cells.\(^{15}\)

MBZ has not yet been tried in human cancer therapy. A previous pilot clinical study of ABZ in patients with advanced colorectal cancer and hepatocellular carcinoma at 10 mg/kg/day for 28 days demonstrated anti-tumor efficacy, but there were concerns about severe neutropenia in 3 of 10 patients.\(^{37}\) On the basis of our preclinical results in GBM and the problems faced by ABZ, we would favor a clinical investigation with MBZ for GBM.

We used a daily dosing for 2 months of 50 mg/kg of MBZ, which translates to 4.1 mg/kg/day based on body surface area.\(^{38}\) MBZ has been extensively used for human for treating echinococcosis, with multiple reports of minimal adverse effects at 50–70 mg/kg/day for 6–24 months of continuous use.\(^{7,8,39}\) MBZ was also reported safe in children at 100–200 mg/kg doses for 12 weeks.\(^{6}\) These reported safe doses suggest...
we could escalate to higher doses than those required for efficacy in animals. In another study of patients with echinococcosis, dosages as high as 200 mg/kg per day for up to 48 weeks were well tolerated, with 8.6 ng/mL (0.029 μM) of MBZ measured in cerebrospinal fluid, compared to 93 ng/mL maximally attained in serum.40 Other studies have shown safe doses up to 200 mg/kg with daily use.6,41,42 With a molecular weight at 295 Da and lipophilic properties, MBZ is capable of passing through the blood-brain barrier.43 In fact, MBZ has effectively treated CNS echinococcosis in numerous clinical settings before, indicating significant CNS penetration of MBZ.44–46

To determine whether combining MBZ with TMZ was beneficial, we chose to use a modest dose of TMZ that had a survival benefit, but not so large as to mask any potential synergy. At 15 mg/kg, TMZ extended the survival rate by 41.4%. The combination of MBZ and TMZ showed a survival benefit of 72.4%, compared with 63.3% for MBZ alone in a separate set of experiments. This difference was not significant for MBZ versus MBZ plus TMZ when comparing these 2 sets of experiments. Also of interest is that TMZ showed efficacy in only 1 of our 2 mouse models, whereas MBZ showed a significant survival difference in both TMZ-susceptible GL261 (IC₅₀ = 6.9 μM) and TMZ-resistant 060919 (IC₅₀ = 149 μM). Of note, patients with TMZ-resistant GBMs make up more than one-half of the patient population.47 A possible next step is to determine whether MBZ has single-agent efficacy in patients for whom initial therapy has failed. In summary, MBZ offers a highly promising opportunity for clinical application on GBM. This is because it has a long track record of safety, there is evidence of preclinical efficacy, an anti-cancer mechanism has been revealed, cost is relatively low, the drug widely available as a generic drug, there is good CNS penetration, and there is a great need for better GBM therapy.

Supplementary Material

Supplementary material is available online at Neuro-Oncology (http://neuro-oncology.oxfordjournals.org/).

Acknowledgments

Support provided by National Institutes of Health Grants R01 NS052507, the Virginia and D.K. Ludwig Fund for Cancer Research, the Johns Hopkins Department of Neurosurgery, Irving J. Sherman, MD, and the Irving J. Sherman Neurosurgery Research Professorship to G.J.R.

Conflict of interest statement. None declared.

References


